ANVS
ANVS clinical trials: Annovis Bio, Inc.
Every trial on ClinicalTrials.gov where Annovis Bio, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ANVS on the catalyst calendar · ANVS registry changes
- Primary completion Dec 2027Sponsor estimatePhase 3NCT06709014A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADAnnovis Bio Inc. · Early Alzheimers DiseaseActive, not recruitingANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2030Sponsor estimatePhase 2/Phase 3NCT07757204An Open-label Long-term Safety Study of Buntanetap in Participants With ADAnnovis Bio Inc. · Alzheimer's Dementia (AD)Not yet recruitingANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2029Sponsor estimatePhase 2/Phase 3NCT07284784A Study of Buntanetap in Participants With PDAnnovis Bio Inc. · Parkinson's Disease (PD)RecruitingANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 13, 2024ActualPhase 2/Phase 3NCT05686044A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADAnnovis Bio Inc. · Alzheimer DiseaseCompletedANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2023ActualPhase 3NCT05357989A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDAnnovis Bio Inc. · Parkinson's Disease, IdiopathicCompletedANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2021ActualPhase 1/Phase 2NCT02925650Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's DiseaseAnnovis Bio Inc. · Alzheimer's DiseaseCompletedANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 16, 2021ActualPhase 1/Phase 2NCT04524351Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's PatientsAnnovis Bio Inc. · Alzheimer DiseaseCompletedANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2010ActualPhase 1NCT01072812Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive ImpairmentAnnovis Bio Inc. · Alzheimer's DiseaseTerminatedANVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner